At iDNA, our mission is to bring science to practice, as a full-service CRO and research institute. Through our unique network and high quality data sets, we can assist with the (co-)development of innovative solutions in software, hardware, and technologies.

At iDNA, our motivation is to bring science to practice. Through extensive collaborations with leading universities, companies and medical centers, we are at the forefront of innovation in screening-related medical device development, drug development, bio-markers, AI imaging algorithm validation, and innovative research. Early detection of diseases such as lung cancer is the future, that we can shape together.

iDNA functions as a full-service CRO dedicated to lung cancer patients. As lung cancer screening will be implemented, a stage shift in diagnosis is likely to happen, resulting in more stage 1 patients. Partners that are shifting their R&D efforts to discover innovations for early stage lung cancer patients, and are looking for early stage lung cancer patients and/or unique data sets, can collaborate with iDNA on:

• Clinical trials for innovative treatments
• Clinical trials for (validation of) biomarkers (ctDNA, liquid biopsy)
• Validation of medical devices
• Validation of AI medical imaging algorithms in unique, high quality data sets (GDPR compliant)

Our expertise goes beyond lung cancer, as co-morbidities in high risk patients such as cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) have been an integral part of our ongoing international research. Through our longstanding collaborations with key opinion leaders, iDNA explores the integration of all these diseases in (cost-)efficient screening protocols.

iDNA can assist in setting up projects and clinical trials related to lung cancer, CVD, or COPD.

Through our international lung cancer screening efforts, we have build a unique data set with high quality CT images, clinical information and clinical history of participants, and biomaterials. Our data sets – that are continuously updated – are 100% GDPR compliant, with full consent of all participants. We have guarantee the safe handling of privacy-sensitive data, while the digital framework of our datasets make it possible to collaborate with public and private parties.